How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

RBM20 as a diagnostic marker for cardiomyopathies and sudden cardiac death

Organization name

ascenion GmbH

Profile

Challenge

Cardiovascular diseases are a major cause of death although considerable financial resources are devoted to both research and therapy. In addition to environmental influences, genetic factors strongly determine a patient's risk for heart disease such as cardiomyopathies and sudden cardiac death. Dilated cardiomyopathy (DCM) is a leading cause for heart failure and cardiac transplantation in Western countries.

Patient-specific determination of risk factors indicating potential development of cardiac diseases is therefore of major importance to improve individual health care, ideally tailor down treatment according to the patientĀ“s individual risk profile and importantly to reduce worldwide therapy costs. For solid risk assessment, markers directly and indirectly related to cardiac function as well as their upstream modulators should be addressed.

Technology

The technology relates to the human RNA binding motif protein RBM20 as a prognostic and diagnostic marker for cardiomyopathies and sudden cardiac death. In particular, the mutation P638L was associated with autosomal dominant DCM and sudden cardiac death, suggesting a relation of RBM20 gene mutations and cardiovascular diseases.

RBM20 acts as a splicing regulator of diverse cardiac genes related to contractile function and disease. Thus, it is not only a suitable diagnostic and therapeutic marker, but could furthermore serve as a control for a larger panel of genes involved in cardiac disease.

Commercial Opportunity

In-licensing for the development of diagnostic tools; collaboration opportunity.

Developmental Status

Change in the RBM20 gene has been identified in a rat model and in patients with DCM and sudden death. Expression of a P638L mutant RBM20 protein transfected into HEK 932 cells reveals a decreased protein/mRNA ratio and an overall reduced RBM20 expression, indicative of reduced protein stability.

Patent Situation

An International Patent Application is pending (unpublished).

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries